2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

628. Aggressive Lymphomas: Cellular Therapies: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Drug-Drug Interactions, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

5437 Clinical outcomes of CD19-directed CAR T-cell therapy (CART) in transformed marginal zone lymphoma versus de novo diffuse large B-cell lymphoma: A multicenter real-world analysis from the ABC consortium

Matthew J. Cortese, MD, MPH, Han Yu, PhD, MBBS2, Megan M Herr, PhD3, Kimberly Newman, MD4, Rahul Kumar Thakur, MD5, Calvin Yee Fen Lee, MD6, Laura Quillen, MD7, Lindsey Fitzgerald, MD8, Nicole Altomare, MD9, Colin J. Thomas, MD10, Omar Elghawy, MD11, Joanna M Rhodes, MD, MSCE12, Ari R. Pelcovits, MD13, Thomas Ollila, MD14, James A Davis, PharmD, BCOP15, Brian Hess, MD16, Megan Melody, MD, MS17, Adam Kidwell, MD18, Tamara K Moyo, MD,PhD19, Jonathon B. Cohen, MD, MS20, Yasmin H Karimi, MD21, Hiffsa Taj, MD, MBBS22, Natalie Jo Hawes, BSN23, Adit Dharia, MD24, Deborah Stephens, DO25, Jonathan Moreira, MD26, Shuo Ma, MD27, Jane N Winter, MD28, Leo Gordon, MD29, Matthew Matasar, MD30, Nirav N. Shah, MD, MS31, Natalie S Grover, MD32, Reem Karmali, MD33, Narendranath Epperla, MD, MS, FACP34
1 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
2 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
3 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
4 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
5 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
6 University of Buffalo, Buffalo, New York, United States
7 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
8 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
9 Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States
10 Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
11 Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
12 Rutgers Cancer Institute, New Brunswick, New Jersey, United States
13 Brown University Health Cancer Institute, Brown University, Providence, Rhode Island, United States
14 Brown University Health Cancer Institute, Brown University, Providence, Rhode Island, United States
15 Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, United States
16 Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, United States
17 Tampa General Hospital Cancer Institute, Tampa, Florida, United States
18 MCW Cancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin, United States
19 Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, United States
20 Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
21 Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan, United States
22 Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States
23 Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States
24 HCA Florida Oak Hill Hospital/ USF Morsani College of Medicine, Tampa, Florida, United States
25 UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, United States
26 Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
27 Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
28 Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
29 Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
30 Rutgers Cancer Institute, New Brunswick, New Jersey, United States
31 MCW Cancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin, United States
32 UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, United States
33 Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
34 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States

Introduction:
CART has significantly improved outcomes for patients (pts) with relapsed/refractory B-cell lymphomas. Although pts with transformed marginal zone lymphoma (tMZL) had inferior survival rates than pts with de novo, non-transformed diffuse large B-cell lymphoma (DLBCL) in the pre-CART era, comparative outcomes following CART remain unclear. This study compares CART clinical outcomes of pts with tMZL versus those with non-transformed DLBCL in a large multicenter, real-world cohort.

Methods:
This multicenter study included pts with DLBCL and tMZL who received CART from 2015 to 2025 across 15 US academic institutions. Differences in demographic, clinical and treatment characteristics were compared using a Wilcoxon rank-sum test for continuous variables and Pearson’s Chi-squared test/Fisher’s exact test for categorical variables. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method and compared between DLBCL and tMZL cohorts using the log-rank test. Median OS and PFS, as well as 3-year and 5-year survival probabilities were reported with 95% confidence intervals. Covariates with univariable association p < 0.05 were included in multivariable Cox proportional hazards and restricted mean survival time (RMST) regression models, with truncation time of 60 months.

Results:
Among 626 pts included in the analysis, with 589 DLBCL and 37 tMZL pts. Baseline characteristics at CART infusion were largely comparable between the cohorts, with no significant differences in median age, sex, race, performance status, stage, serum LDH, or IPI score. The prevalence of double-hit lymphoma (DHL) was similar between cohorts (55% DLBCL vs. 41% tMZL; p=0.203), while double-expressor lymphoma (DEL) was more common in the DLBCL cohort (85%, vs 58% in tMZL; p=0.034). Frontline R-CHOP use was comparable between cohorts (both 70%). DLBCL pts received more DA-EPOCH-R (18% vs. 2.5%; p=0.002), whereas tMZL pts were more likely to have had prior bendamustine (7.7% vs. 1.5%; p=0.030). There were no significant differences between cohorts for prior lines of therapy (LOT), autologous or allogeneic transplantation rate, CART product, bridging therapy, or vein-to-vein time.

At a median follow-up of 34.9 mo for DLBCL pts and 34.8 mo for tMZL pts, there was no statistically significant difference in PFS or OS. The median PFS of DLBCL was 6.64 mo (95%CI 5.42-10.09) vs not reached (NR) for tMZL (95%CI 3.75-NR) and median OS for DLBCL was 26.84 mo (95% CI 20.76-34.46) vs NR for tMZL (95% CI 17.51-NR) following CART. Pts with tMZL, however, demonstrated numerically but superior PFS and OS; 3-yr and 5-yr PFS rates were 48.7% and 48.7% for tMZL vs 32.7% and 28.3% for DLBCL, and the corresponding OS rates were 61.6% and 61.6% for tMZL vs 44.5% and 40.2% for DLBCL.

In multivariable analysis for all pts, >2 LOT and IPI >2 were the strongest adverse prognostic factors for both PFS (>2 LOT HR 1.57, p=0.001 and IPI >2 HR 1.42, p=0.013) and OS (>2 LOT HR 2.00, p <0.001 and IPI >2 HR 1.59, p 0.003). DLBCL and tMZL had similar risks of treatment failure and death (PFS HR for tMZL=0.72, 95%CI 0.37-1.42, p=0.35; OS HR for tMZL=0.72, 95%CI 0.37-1.42, p=0.35).

The incidence, severity, timing, and duration of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were comparable between the two cohorts. 19% of DLBCL and 15% of tMZL pts had grade ≥3 CRS or ICANS (p=0.522).

Among pts who received bispecific antibody (BsAb)-based salvage post-CART progression (overall N=90; DLBCL N=81, tMZL N=9), baseline characteristics were well balanced between groups. Pts with tMZL had numerically higher overall response rates (78% tMZL vs 63% DLBCL, p= 0.482) and complete response rates (56% tMZL vs 40% DLBCL) than DLBCL, although these differences were not statistically significant (p=0.482 and 0.479, respectively).

Conclusion:
This study represents the largest real-world comparison of clinical outcomes in pts with tMZL and DLBCL treated with CART. Although tMZL and DLBCL are biologically distinct diseases, our findings suggest that CART and subsequent salvage with BsAb following CAR T-cell failure achieves comparable clinical outcomes in both cohorts, with a trend toward improved long-term outcomes in pts with tMZL. Prospective clinical studies with integrated translational analyses are warranted to validate these findings and further define the biological mechanisms underlying response.

Matthew J. Cortese, MD, MPH: Adaptive Biotechnologies - Honoraria; Abbvie - Honoraria; SignifyMD - Honoraria; MJH Events - OncLive/PER - Honoraria; Bristol Myers Squibb - Honoraria; AstraZeneca - Honoraria; Binaytara Foundation - Honoraria; Curio Science - Honoraria; CCO/Decera - Honoraria; Merck - Research Funding; ADC Therapeutics - Consultancy (Includes expert testimony); Adaptive Biotechnologies - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Synthekine LLC - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony)